When: Two consecutive closes above $378.87 with 50 SMA slope flattening and volume >2.5M shares — approximately 1 week pending but not triggered

Then: Framework stalled; mid-tier-drift failure mode per 9/14 reflection

When: 3-5 sessions closing above $375 on above-average volume

Then: Staged tranche add

When: Price breakout above $393 with volume confirmation

Then: Second staged tranche add

HOLD - staged adds at $375 (confirmation) and $393 (breakout); preserve existing exposure without deploying new capital into tightening macro

• 10-year Treasury hit 5% this week, highest level since 2007
• Polymarket pricing 94% probability of no Fed cuts in 2026
• Oil briefly touched $105
• July 17 capitulation volume: 11.56 million shares on base of 1.5-3 million
• Receivables grew 27.3% against revenue growth of 18.5% (9 percentage point outperformance)
• ISRG 31x forward P/E at high end of 10-year range relative to 10-year yield
• Earnings yield approximately 3.2% against 5% risk-free rate (negative real)
• 1.76 PEG ratio vulnerable if growth assumptions are cut
• Entry at $377, stop at $344: 8.8% downside risk to stop
• T1 target $415-$420: approximately 10-11% upside (1.1:1 risk/reward)
• T2 at 200 SMA zone $445-$455: 21% move from entry, requires multiple simultaneous tail scenarios
• ISRG beta of 1.465: will underperform in broad market selloffs
• Management confirmed U.S. procedure deceleration and policy-related hospital uncertainty at Wells Fargo conference September 11

→ vs aggressive: Disputes 'macro already priced in' conclusion: drawdowns have no memory and multiples can compress further when discount rates are still rising; current macro is actually tightening, not easing

→ vs aggressive: Capitulation identifies supply exhaustion, not absence of forward demand; textbook climax volumes in 2022 preceded further legs down before true bottoms formed

→ vs aggressive: Receivables outpacing revenue by 9 percentage points is hallmark of collection slippage or channel stuffing, not purely anticipatory stocking; management itself confirmed U.S. procedure deceleration

→ vs aggressive: 31x forward P/E with 3.2% earnings yield against 5% risk-free rate is not a 'gift'; historically ISRG has not bottomed until earnings yield gap versus treasuries narrowed, typically through price compression

→ vs aggressive: Risk/reward is 1.1:1, not 2:1 as claimed; T2 target requires macro easing, hospital capex absorption of oil at $100+, U.S. procedure reversal, death cross failure, and sentiment regime change simultaneously—multiple low probability assumptions in sequence

HOLD with staged tranche structure: 25% on confirmation above $375 (3-5 sessions above-average volume), 25% on breakout above $393 with volume, 50% reserved for retest on declining volume; add cash-secured put overlay at $340-$350 strikes to collect premium while waiting for better entry or confirmation

• Capitulation print on July 17 with 11.56 million shares vs normal base of 1.5-3 million is textbook bottom volume signature
• September 8 retest at $347.52 holding above July low of $344.55 confirms constructive higher-low behavior
• MACD flipped positive for first time in two months; RSI at 52 with room to run toward 65
• 10-year yield at 5% with Polymarket pricing 94% probability of no Fed cuts in 2026 is materially worse macro than when January $594 high was made
• Oil briefly touched $105
• Entry at $377 with stop at $344 is 8.8% downside vs T1 target of $415-$420 at only 10-11% upside—approximately 1.1:1 reward-to-risk, not 2:1
• ISRG has $5.22 billion in cash, zero debt, and 33.6% operating margin that expanded 310 basis points YoY
• Quarterly free cash flow hit $948 million, up 69% YoY
• Gross margin expanded 150 basis points in Q2; EPS grew 26.5% YoY
• First CE mark for da Vinci SP in transvaginal gynecology represents real TAM expansion
• 14-million procedure meta-analysis reinforces clinical moat
• 1.465 beta means underperformance in broad risk-off moves
• Receivables outpacing revenue by 9 percentage points is genuinely concerning
• Management acknowledged U.S. procedure deceleration at Wells Fargo conference
• Breakout above $393 with above-average volume triggers second tranche addition
• July low of $344.55 serves as explicit invalidation level if violated

→ vs aggressive: Macro overhang is not priced in—the 42% decline occurred when yields were lower and Fed was expected to cut; that expectation has been completely removed from markets. The 10-year at 5% and oil at $105 represent actively tightening conditions, not a known discount

→ vs aggressive: Reward-to-risk math is incorrect: entry at $377 with stop at $344 yields only 1.1:1, not 2:1. T2 target at 200 SMA zone requires macro easing, U.S. procedure reacceleration, oil relief, and sentiment regime change simultaneously—a tail scenario being treated as the base case

→ vs conservative: ISRG is a defensive compounder with fortress balance sheet and accelerating fundamentals (69% FCF growth, 26.5% EPS growth, 33.6% operating margin expansion), not a deteriorating momentum name. Fundamentals are accelerating while the stock has been dragged by rate-sensitive multiple compression

→ vs conservative: Higher-low formation at September 8, bullish MACD cross, and volume-supported bounce off $347 indicate supply has been absorbed. The stock did not break the July low—it bounced. The market is demonstrating the asymmetric downside case is not playing out as claimed

→ vs conservative: Receivables outpacing revenue by 9 percentage points and U.S. procedure deceleration are valid concerns but do not justify treating a zero-debt company with $5.22B cash as an abandoned quality franchise